Dr. Peter Johann is a Managing General Partner of NGN Capital. He joined from Boehringer Ingelheim where he was the Division Head of Corporate Development. Dr. Johann has established a worldwide network in the Biotech and Pharmaceutical Industry. His responsibilities at Boehringer Ingelheim included strategic planning, strategic projects, M&A, business development and licensing. He identified and evaluated several licensing, M&A and co-promotion deals. Prior to this Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader where he led global business teams and was responsible for global marketing of oncology products as well as evaluation of pipeline products from internal and external sources. Dr. Johann joined Roche from Boehringer Mannheim where he was Head of Business Development and Marketing Molecular Medicine. Besides marketing activities Dr. Johann was involved in setting up and managing joint venture companies as member of the supervisory board. He was also responsible for licensing activities in this field. Prior to that position he had Marketing, Sales and Business Development responsibilities at Boehringer Mannheim Biochemicals, among others, for collaborations in the field of Biopharmaceuticals. Dr. Johann has additional industry experience in Business Development and Marketing of pharmaceutical products with Kaneka in Japan and with Röhm in Germany in industrial enzymes. Dr. Johann obtained his Ph.D. from the Technical University Munich. He currently serves on the Board of Directors of Exosome Diagnostics Inc. and Vivaldi Biosciences, Inc.. He previously served on the Board of Directors of Horizon Pharma Inc, Resverlogix Corp., Zenith Epigenetics Inc., Endosense SA acquired by St. Jude Medical, Jerini AG, acquired by Shire Pharmaceuticals, Noxxon Pharma AG, Micromet Inc., which was acquired by Amgen and NaniRx Therapeutics and as an observer on the board of Santhera Pharmaceuticals AG and Cerapedics, Inc.